Ponesimod reduces annualized relapse rate, compared with teriflunomideSeptember 12, 2019Multiple Sclerosis
Continuous treatment reduces risk of confirmed disability progression in MSSeptember 12, 2019Multiple Sclerosis
Steady advances made since recognition of neuromyelitis optica 20 years agoJune 4, 2019Multiple Sclerosis